Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 601474
                    [Title] => Roche drug shows longest overall survival  for patients with advanced lung cancer
                    [Summary] => 
BASEL, Switzerland — Roche announced updated results from a late-stage study demonstrating that first-line use of bevacizumab provided the longest median overall survival duration shown in a Phase III trial of patients with advanced non-small cell adenocarcinoma of the lung.
                    [DatePublished] => 2010-08-12 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

EASTERN COOPERATIVE ONCOLOGY GROUP

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 601474
                    [Title] => Roche drug shows longest overall survival  for patients with advanced lung cancer
                    [Summary] => 
BASEL, Switzerland — Roche announced updated results from a late-stage study demonstrating that first-line use of bevacizumab provided the longest median overall survival duration shown in a Phase III trial of patients with advanced non-small cell adenocarcinoma of the lung.
                    [DatePublished] => 2010-08-12 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

Roche drug shows longest overall survival for patients with advanced lung cancer

August 12, 2010 - 12:00am

BASEL, Switzerland — Roche announced updated results from a late-stage study demonstrating that first-line use of bevacizumab provided the longest median overall survival duration shown in a Phase III trial...

Science and Environment